Drug-Eluting Vascular Stent System
The Eluvia Stent is the first and only drug-eluting technology designed to deliver controlled, localized, low-dose amorphous paclitaxel to the target lesion. Eluvia is built on the Innova Stent platform, which was designed to address the unique challenges of the SFA with the optimal amount of strength, flexibility and fracture resistance. In the IMPERIAL RCT, Eluvia demonstrated a statistically significantly higher primary patency* rate and half the TLR rate compared to Zilver PTX at 12 months.
* 12-Month Kaplan-Meier Estimate Primary Patency Rate